Key Insights

Highlights

Treatment Research

3 treatments under study, led by Psma Pet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Unknown1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06923657Not ApplicableRecruiting

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

NCT04967001Not ApplicableUnknown

68Ga-PSMA PET in the Prostate Cancer

Showing all 2 trials

Research Network

Common Treatments

  • Psma Pet1
  • Psma Petmritrus Guided Prostate Targeted Combined Saturation Biopsy1
  • Trus Guided Transperineal Saturation Biopsy1

Active Sponsors

  • Xijing Hospital1
  • First Affiliated Hospital of Fujian Medical University1

Related Conditions

  • Metastases1
  • Prostate Cancer Screening1
  • Prostatic Neoplasms1

Activity Timeline